| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma (NCT07595913) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2026-07-01 |
| A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. (NCT07565597) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2026-05-12 |
| Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (NCT07231445) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2026-04-21 |
| Study of ZGGS34 in Participants With Advanced Solid Tumors (NCT07258121) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-12-31 |
| Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (NCT07189455) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-12-12 |
| Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (NCT07099547) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-12-02 |
| ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (NCT07038096) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-09-23 |
| Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (NCT07080216) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-09-23 |
| Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors (NCT07142837) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-09-01 |
| Study of ZG006 in Participants With Neuroendocrine Prostate Cancer (NCT07024277) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-08-01 |
| Study of ZG005 in Patients With Advanced Solid Tumors (NCT06927687) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-06-13 |
| Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (NCT06938880) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-05-20 |
| Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (NCT06883526) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-05-16 |
| A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer (NCT06592638) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-03-31 |
| A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. (NCT04971551) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-12-01 |
| Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma (NCT06558227) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-10-24 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer (NCT06283719) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-09-02 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (NCT06440057) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-08-29 |
| A Safety and Tolerability Study of Jaktinib (NCT05279001) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-07-01 |
| Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. (NCT06372626) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-05-30 |
| A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor (NCT06239298) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-05-10 |
| A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia (NCT05688839) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-04-01 |
| Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma (NCT06241235) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-03-27 |
| A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants (NCT06193148) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-03-19 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) (NCT05861128) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-11-10 |
| Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (NCT05978284) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-10-27 |
| Study of ZG0895.HCl in Patients With Advanced Solid Tumors (NCT05877664) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-08-08 |
| Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) (NCT05861102) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-07-20 |
| A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis (NCT05676242) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2023-01-11 |
| Study of ZGGS18 in Patients With Advanced Solid Tumors (NCT05584800) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-11-15 |
| Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) (NCT05702788) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-09-01 |
| A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis (NCT05526222) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-07-14 |
| A Study of ZG005 in Patients With Advanced Solid Tumors (NCT06233292) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-06-17 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (NCT05255237) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-03-25 |
| ADME Study of [14C]-Jaktinib in Healthy Male Subjects (NCT05150717) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-01-04 |
| A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers (NCT06246695) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-10-27 |
| Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer (NCT04964284) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-10-06 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. (NCT04866056) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-30 |
| Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal (NCT04971473) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-10 |
| Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (NCT05051761) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-04 |
| Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function (NCT04993404) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-08-27 |
| Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. (NCT04851535) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-07-28 |
| A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (NCT04612699) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-03-11 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis (NCT04617028) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-02-05 |
| A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors (NCT04612712) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-01-19 |
| Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma (NCT04605185) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-01-08 |
| Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis (NCT04539639) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-12-02 |
| Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis (NCT04507659) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-12-01 |
| The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (NCT04447183) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-11-23 |
| Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (NCT04503902) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-15 |
| A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors (NCT04472858) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-15 |
| Jaktinib Hydrochloride Cream For Atopic Dermatitis (NCT04435392) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-14 |
| Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis (NCT04312594) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-09-08 |
| A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (NCT04445363) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-08-12 |
| Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (NCT04211922) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-01-21 |
| Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis (NCT04217993) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-01-07 |
| To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects (NCT04032821) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-11-20 |
| Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata (NCT04034134) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-11-18 |
| Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis (NCT04459871) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-11-11 |
| Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients (NCT04137185) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-06-10 |
| Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. (NCT03886415) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-01-08 |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML (NCT04402723) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-11-06 |
| Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer (NCT03607188) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-10-18 |
| The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man (NCT04816123) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-10-09 |
| A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer (NCT03602495) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2018-08-29 |
| Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy (NCT03611426) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2017-11-29 |
| The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers (NCT03314402) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2017-09-28 |